Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Spratlin JL, et al. Among authors: lewis nl. J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048182 Free PMC article. Clinical Trial.
Oral fluoropyrimidines in cancer treatment.
Lewis NL, Meropol NJ. Lewis NL, et al. Cancer Invest. 2000;18(8):747-60. doi: 10.3109/07357900009012207. Cancer Invest. 2000. PMID: 11107445 Review. No abstract available.
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Lewis NL, et al. Cancer Chemother Pharmacol. 2002 Oct;50(4):257-65. doi: 10.1007/s00280-002-0500-0. Epub 2002 Aug 21. Cancer Chemother Pharmacol. 2002. PMID: 12357298 Clinical Trial.
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Cohen SJ, et al. Among authors: lewis nl. J Clin Oncol. 2003 Apr 1;21(7):1301-6. doi: 10.1200/JCO.2003.08.040. J Clin Oncol. 2003. PMID: 12663718 Clinical Trial.
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. Cohen SJ, et al. Among authors: lewis nl. Cancer Chemother Pharmacol. 2004 Jun;53(6):513-8. doi: 10.1007/s00280-004-0764-7. Epub 2004 Feb 3. Cancer Chemother Pharmacol. 2004. PMID: 14760509 Clinical Trial.
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.
Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A. Freedman GM, et al. Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1389-93. doi: 10.1016/j.ijrobp.2006.11.017. Int J Radiat Oncol Biol Phys. 2007. PMID: 17394942 Clinical Trial.
Effects of food on the relative bioavailability of lapatinib in cancer patients.
Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, Stead A, Beelen AP, Lewis LD. Koch KM, et al. Among authors: lewis ld, lewis nl. J Clin Oncol. 2009 Mar 10;27(8):1191-6. doi: 10.1200/JCO.2008.18.3285. Epub 2009 Feb 2. J Clin Oncol. 2009. PMID: 19188677 Free PMC article. Clinical Trial.
56 results